Symbicort Turbuhaler approved for asthma in Japan
20 October 2009
Ian Haydock
Please Login to read the full article.
20 October 2009
Ian Haydock
ian.haydock@informa.com
AstraZeneca's inhaled combination asthma product Symbicort has been formally approved in Japan for the maintenance treatment of bronchial asthma in patients aged 16 years or older.
The twice-daily product, administered through the Turbuhaler dry powder inhaler system, contains 160µg...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Does Vectura's US deal on respiratory drug mean FDA is softening on approval pathway?
- GSK sees £3 billion wiped off value in response to mixed Phase III Relovair data
- Pivotal trials boost Relovair from GSK/ Theravance in COPD
- Symbicort study provides insight into asthma treatment for African-Americans
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
